| Literature DB >> 35878292 |
Hsin-Tzu Yeh1,2, Hsien-Yi Chen1,2, Sung-Wei Liu3,4, Te-I Weng5,6,7, Cheng-Chung Fang5,6, Jiun-Hao Yu8, Yen-Chia Chen9,10,11, Yu-Jang Su12,13,14,15, Shi-Ying Gao1,2, Chih-Chuan Lin1,2.
Abstract
Predictors of mortality in illicit drug users involving Novel Psychoactive Substances (NPS) and multiple substances have not been elucidated. We aimed to define predictors of mortality in the NPS endemic era's illicit drug users to strengthen patient care in emergency treatment. This was a retrospective study. LC-MS/MS-confirmed positive illicit drug users who visited the emergency departments (ED) of six medical systems were enrolled. Demographic information, physical examinations, and laboratory data were abstracted for mortality analysis. There were 16 fatalities in 355 enrolled patients. The most frequently used illicit drugs were amphetamines, followed by opioids, cathinones, and ketamine. The most frequently detected cathinones among the 16 synthetic cathinones were eutylone, followed by mephedrone. The combined use of cathinones and ketamine was most commonly observed in our results. Univariate analysis revealed that the mortality patients were older, with deep coma, faster heart rate and respiratory rate, lower blood pressures and O2 room air saturation, more seizures, abnormal breath sounds, and had urine incontinence compared to the survivor patients. The mortality patients also had acute kidney injury, higher potassium, blood sugar, liver function test, and lactate level. The results of multiple logistic regression demonstrated that SBP < 90 mmHg, dyspnea, blood sugar > 140 mg/dl, and HCO3 < 20.6 mmHg were independent predictors of in-hospital mortality. Regardless of the pattern of the use of illicit drugs, the predictors allow for risk stratification and determining the optimal treatment.Entities:
Keywords: mortality; new psychoactive substance; prediction
Year: 2022 PMID: 35878292 PMCID: PMC9317329 DOI: 10.3390/toxics10070386
Source DB: PubMed Journal: Toxics ISSN: 2305-6304
The clinical manifestations of the main drug classes.
| Variable | Drugs |
| |||
|---|---|---|---|---|---|
| Amphetamines ( | Opioids ( | Cathinones ( | Ketamine ( | ||
| Age | 38.44 ± 11.07 | 48.43 ± 18.46 | 29.50 ± 12.70 | 40.33 ± 15.93 | <0.01 |
| Male, | 51 (77.27) | 42 (68.85) | 23 (63.89) | 23 (85.19) | 0.19 |
| Triage vital signs | |||||
| Body temperature (°C) | 36.74 ± 0.91 | 36.73 ± 1.04 | 37.36 ± 1.44 | 36.73 ± 0.84 | 0.02 |
| Heart rate (beats/min) | 107.61 ± 25 | 100.03 ± 19.02 | 113.86 ± 30.25 | 103.70 ± 27.48 | 0.06 |
| Respiratory rate (/min) | 19.82 ± 2.68 | 19.87 ± 3.04 | 19.97 ± 4.38 | 19.27 ± 4.72 | 0.87 |
| SBP (mmHg) | 133.48 ± 27.84 | 123.05 ± 23.94 | 132.6 ± 24.74 | 131.38 ± 33.01 | 0.14 |
| DBP (mmHg) | 82.33 ± 19.92 | 78.31 ± 18.74 | 84.86 ± 20.92 | 76.85 ± 19.42 | 0.27 |
| MAP (mmHg) | 99.38 ± 21.41 | 93.22 ± 19.15 | 100.77 ± 20.82 | 95.03 ± 22.44 | 0.24 |
| SpO2 (%) | 94.65 ± 7.14 | 93.48 ± 6.84 | 95.78 ± 6.10 | 96.45 ± 4.38 | 0.32 |
| GCS ≤ 8, | 5 (7.58) | 17 (27.87) | 8 (22.22) | 8 (29.63) | 0.02 |
| Symptoms/signs | |||||
| Palpitation | 3 (4.55) | 0 (0) | 5 (13.89) | 2 (7.41) | 0.03 |
| Chest pain | 1 (1.52) | 2 (3.28) | 1 (2.78) | 3 (11.11) | 0.16 |
| Dyspnea | 5 (7.58) | 10 (16.39) | 6 (16.67) | 2 (7.41) | 0.31 |
| Nausea/vomiting | 1 (1.52) | 6 (9.84) | 5 (13.89) | 1 (3.70) | 0.07 |
| Headache | 1 (1.52) | 3 (4.92) | 3 (8.33) | 0 (0) | 0.22 |
| Hallucination | 9 (13.64) | 1 (1.64) | 5 (13.89) | 1 (3.70) | 0.04 |
| Agitation/delirium | 24 (36.36) | 6 (9.84) | 15 (41.67) | 4 (14.81) | <0.01 |
| Seizure/status epilepticus | 4 (6.06) | 4 (6.56) | 4 (11.11) | 2 (7.41) | 0.81 |
| Tremor | 4 (6.06) | 4 (6.56) | 3 (8.33) | 0 (0) | 0.54 |
| Pupil size | 3 (3–3) | 2.75 (2–3) | 3 (2–3) | 3 (2–3) | 0.02 |
| Abnormal breath sound (wheezing+ crackle) | 3 (4.55) | 9 (14.75) | 3 (8.33) | 1 (3.70) | 0.16 |
| Urine incontinence | 2 (3.03) | 6 (9.84) | 0 (0) | 0 (0) | 0.05 |
| Sweating | 3 (4.55) | 2 (3.28) | 1 (2.78) | 2 (7.41) | 0.80 |
| Myoclonus/rigidity | 1 (1.52) | 1 (1.64) | 3 (8.33) | 1 (3.70) | 0.24 |
| Laboratory findings | |||||
| WBC | 10.07 ± 4.63 | 12.81 ± 7.3 | 12 ± 5.25 | 12.45 ± 11.38 | 0.15 |
| Hct | 41.59 ± 5.67 | 39.12 ± 6.08 | 42.32 ± 5.31± | 40.97 ± 7.89 | 0.01 |
| Platelet | 260.53 ± 95.05 | 257.74 ± 112.54 | 322.5 ± 84.1 | 273.59 ± 125.07 | 0.01 |
| Creatinine | 1.12 ± 1.19 | 1.24 ± 1.1 | 1.56 ± 1.9 | 1.47 ± 1.46 | 0.03 |
| Na (Sodium) | 137.61 ± 5.9 | 137.06 ± 7.33 | 139.66 ± 5.06 | 136.64 ± 4.51 | 0.05 |
| K (Potassium) | 3.79 ± 0.75 | 3.92 ± 0.72 | 3.72 ± 0.68 | 3.95 ± 0.58 | 0.10 |
| Cl (Chloride) | 100.27 ± 7.06 | 103.67 ± 7.09 | 105.29 ± 6.45 | 102.36 ± 8.86 | 0.68 |
| Sugar | 129.98 ± 42.46 | 150.22 ± 101.44 | 128.69 ± 47.8 | 128.4 ± 42.71 | 0.72 |
| CPK | 257.5 (116.5–463.5) | 182 (155–317) | 282 (194–908) | 472.5 (171–1819) | 0.14 |
| AST | 62 (36–129) | 37.5 (26.5–54.5) | 19 (18–29) | 30.5 (24–89) | 0.01 |
| ALT | 30 (15–59) | 27.5 (18–48) | 17.5 (13–35) | 26 (14–33) | 0.29 |
| Bilirubin total | 0.57 (0.36–1.15) | 0.58 (0.35–0.9) | 0.69 (0.5–1.2) | 0.51 (0.34–0.85) | 0.66 |
| Lactate | 2.4 (1.37–6.01) | 2.31 (1.65–3.2) | 2.59 (1.63–6.98) | 2.4 (1.28–5.14) | 0.75 |
| pH | 7.37 ± 0.1 | 7.33 ± 0.11 | 7.4 ± 0.08 | 7.37 ± 0.09 | 0.04 |
| PCO2 | 39.22 ± 10.07 | 47.2 ± 16.51 | 37.99 ± 10.88 | 37.97 ± 9.97 | 0.02 |
| HCO3 | 22.37 ± 5.64 | 23.77 ± 5.88 | 22.63 ± 6.44 | 20.75 ± 5.2 | 0.21 |
Characteristics of the illicit drug users on arrival at the ED of survivors and mortality patients.
| Variable | Patients |
| ||
|---|---|---|---|---|
| All ( | Survivor ( | Mortality ( | ||
| Age | 39.32 ± 15.7 | 38.81 ± 15.6 | 49.94 ± 18.8 | 0.01 |
| Male, | 233 (65.63) | 223 (65.78) | 10 (62.50) | 0.10 |
| Triage vital signs | ||||
| Body temperature (°C) | 36.85 ± 1.1 | 36.82 ± 1.0 | 37.38 ± 2.0 | 0.59 |
| Heart rate (beats/min) | 105.63 ± 26.0 | 104.61 ± 25.5 | 127.19 ± 28.3 | 0.00 |
| Respiratory rate (/min) | 19.8 ±3.2 | 19.65 ± 3.0 | 23.13 ± 5.8 | 0.01 |
| SBP (mmHg) | 126.02 ± 27.2 | 127.01 ± 26.8 | 105.38 ± 28.9 | 0.01 |
| DBP (mmHg) | 78.36 ± 19.9 | 78.78 ± 19.2 | 69.5 ± 30.3 | 0.01 |
| MAP (mmHg) | 94.25 ± 21.0 | 94.86 ± 20.4 | 81.46 ± 29.0 | 0.01 |
| SpO2 (%) | 95.16 ± 6.6 | 95.5 ± 6.2 | 89.17 ± 8.8 | 0.01 |
| GCS ≤ 8, | 68 (19.15) | 59 (17.40) | 9 (56.25) | 0.0008 |
Count data are expressed as numbers (percentage) and continuous values are expressed as mean ± SD.
Clinical presentations of the illicit drug users on arrival at the ED of survivors and mortality patients.
| Variable | Patients |
| ||
|---|---|---|---|---|
| All ( | Survivor ( | Mortality ( | ||
| Palpitation | 19 (5.35) | 18 (5.31) | 1 (6.25) | 0.59 |
| Chest pain | 15 (4.23) | 14 (4.13) | 1 (6.25) | 0.51 |
| Dyspnea | 38 (10.70) | 30 (8.85) | 8 (50) | <0.00 |
| Nausea/vomiting | 22 (6.20) | 22 (6.49) | 0 (0) | 1 |
| Headache | 13 (3.66) | 13 (3.83) | 0 (0) | 1 |
| Hallucination | 26 (7.32) | 25 (7.37) | 1 (6.25) | 0.71 |
| Agitation/delirium | 92 (25.92) | 89 (26.25) | 3 (18.75) | 0.83 |
| Seizure/status epilepticus | 19 (5.35) | 15 (4.42) | 4 (25) | 0.00 |
| Tremor | 18 (5.07) | 16 (4.72) | 2 (12.50) | 0.19 |
| Pupil size(left) | 2.83 ± 1.1 | 2.79 ± 1.0 | 3.68 ± 2.2 | 0.31 |
| Pupil size(right) | 2.84 ± 1.1 | 2.79 ± 1.0 | 3.68 ± 2.2 | 0.32 |
| Abnormal breath sound (wheezing + crackle) | 23 (6.48) | 18 (5.31) | 5 (31.25) | 0.00 |
| Urine incontinence | 16 (4.51) | 13 (3.83) | 3 (18.75) | 0.03 |
| Sweating | 25 (7.04) | 22 (6.49) | 3 (18.75) | 0.09 |
| Myoclonus/rigidity | 13 (3.66) | 12 (3.54) | 1 (6.25) | 0.46 |
Count data are expressed as numbers (percentage) and continuous values are expressed as mean ± SD.
Initial Laboratory data of the illicit drug users of survivors and mortality patients.
| Variable | Patients |
| ||
|---|---|---|---|---|
| All ( | Survivor ( | Mortality ( | ||
| WBC (103/uL) | 11.77 ± 7.2 | 11.72 ± 7.1 | 12.65 ± 7.4 | 0.41 |
| Hct (%) | 40.58 ± 6.1 | 40.76 ± 6.0 | 36.72 ± 8.9 | 0.06 |
| Platelet (103/uL) | 270.19 ± 101.1 | 273.98 ± 98.3 | 193.44 ± 128.2 | 0.01 |
| Creatinine (mg/dL) | 1.28 ± 1.5 | 1.24 ± 1.5 | 2.06 ± 1.2 | <0.00 |
| Na (Sodium, mEq/L) | 137.9 ± 5.3 | 138.09 ± 5.0 | 133.94 ± 9.2 | 0.22 |
| K (Potassium, mEq/L) | 3.83 ± 0.7 | 3.78 ± 0.6 | 4.94 ± 1.2 | <0.00 |
| Cl (Chloride, mEq/L) | 103.42 ± 5.7 | 103.51 ± 5.7 | 102.78 ± 6.0 | 0.97 |
| Blood sugar (mg/dl) | 129.42 ± 63.0 | 126.54 ± 52.8 | 181.13 ± 154.6 | 0.02 |
| CPK (U/L) | 223 (109–687) | 223 (106–633) | 241 (182–1336) | 0.57 |
| AST (U/L) | 35.5 (22–84) | 33 (21–62) | 214 (76–2388) | <0.00 |
| ALT (U/L) | 24 (14–46) | 24 (14–39) | 47 (19–131) | 0.01 |
| Total bilirubin (mg/dl) | 0.63 (0.4–1.1) | 0.6 (0.4–1) | 1.79 (0.8–3.5) | 0.01 |
| Lactate (mmol/L) | 2.33 (1.45–3.68) | 2.23 (1.39–3.65) | 3.44 (2.71–9.24) | 0.01 |
| PH | 7.36 ± 0.1 | 7.36 ± 0.1 | 7.35 ± 0.1 | 0.58 |
| FiO2 (%) | 45.08 ±33.1 | 41.98 ± 32.0 | 81.43 ± 24.1 | 0.00 |
| PCO2 (mmHg) | 41.5 ± 11.9 | 42 ± 11.9 | 33.67 ± 8.5 | 0.01 |
| HCO3 (mmol/L) | 22.69 ± 5.3 | 23.06 ± 5.1 | 16.87 ± 4.8 | <0.00 |
Count data are expressed as numbers (percentage) and continuous values are expressed as mean ± SD or mean (Q1–Q3).
Logistic model for predicting the probability of mortality of drug users.
| Variable | β | Odds Ratio | 95% Confidence Interval |
|
|---|---|---|---|---|
| Intercept | −1.8852 | |||
| SBP < 90 | 1.1441 | 9.86 | (1.128, 86.129) | 0.04 |
| Dyspnea | 1.4174 | 17.03 | (2.947, 98.368) | <0.01 |
| Sugar > 140 | 1.1644 | 10.27 | (1.196, 88.117) | 0.03 |
| HCO3 < 20.6 | 1.2959 | 13.35 | (1.774, 100.506) | 0.01 |
Figure 1Receiver operating characteristic (ROC) curves for the prediction of the in-hospital mortality.